Investigating how RNA modifications contribute to lung blood vessel changes in pulmonary arterial hypertension.

Novel roles of RNA modifications in the pathogenesis of pulmonary vascular remodeling and PAH

['FUNDING_R01'] · LURIE CHILDREN'S HOSPITAL OF CHICAGO · NIH-10897941

This study is looking at how changes in RNA might contribute to pulmonary arterial hypertension (PAH), a condition that raises blood pressure in the lungs, and aims to find new ways to help people with PAH by understanding how these changes affect important genes.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorLURIE CHILDREN'S HOSPITAL OF CHICAGO (nih funded)
Locations1 site (CHICAGO, UNITED STATES)
Trial IDNIH-10897941 on ClinicalTrials.gov

What this research studies

This research focuses on understanding the role of RNA modifications in the development of pulmonary arterial hypertension (PAH), a serious condition that leads to increased pressure in the lungs and can result in heart failure. The study aims to explore how these RNA modifications affect the expression of genes involved in vascular remodeling, which is a key feature of PAH. By utilizing advanced techniques like CRISPR, researchers will investigate the molecular mechanisms that underlie these changes, potentially leading to new therapeutic targets for patients suffering from PAH.

Who could benefit from this research

Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with pulmonary arterial hypertension.

Not a fit: Patients with pulmonary arterial hypertension who do not have the specific RNA modification profiles being studied may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to novel treatments that more effectively target the underlying causes of pulmonary arterial hypertension, improving patient outcomes.

How similar studies have performed: While the role of RNA modifications in other diseases has been explored, this specific investigation into their impact on pulmonary arterial hypertension is relatively novel and has not been extensively tested.

Where this research is happening

CHICAGO, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.